KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

(4:20)

KEYNOTE-042: revolutionizing lung cancer treatment with pembrolizumab monotherapy

(1:14)

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer

(53)

Keynote: Cancer Genomics, Big Data, Bigger Questions

(33:20)

KEYNOTE-775 subgroup analysis in advanced endometrial cancer

(3:28)

KEYNOTE-826: pembrolizumab + chemotherapy vs placebo + chemotherapy for cervical cancer

(7:18)

2022 ASCO GI Cancers Symposium Keynote: Precision Medicine, AI and Innovation

(32:57)

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC

(5:1econd)

Jodi-ann Goulter Empowering Corporate Women to Reclaim Balance, Recharge Energy, and thrive

(29:14)

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

(3:9)

Keynote 671: Perioperative Pembrolizumab for NSCLC - OncTalk Lung 2023

(2:)

Keynote Presentation: Cancer Immune Interception in Lynch Syndrome

(29:15)

2022 ASCO GU Cancers Symposium Keynote | A Path Forward: Addressing Disparities in GU Cancers

(29:57)

Mary Elizabeth Williams, Cancer Patient Advocate Keynote - 2019 CRI Immunotherapy Patient Summit NYC

(23:39)

Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12

(18:38)

KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC

(2:53)

KEYNOTE-355: pembrolizumab in triple-negative breast cancer

(2:7)

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

(4:20)

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

(7:23)

Young-Onset Colorectal Cancer Center Annual Forum Research Keynote

(57:39)